Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Athira Pharma Inc (ATHA)

Athira Pharma Inc (ATHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,869
  • Shares Outstanding, K 38,329
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,670 K
  • 60-Month Beta 2.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.19
Trade ATHA with:

Options Overview Details

View History
  • Implied Volatility 563.43% ( -10.45%)
  • Historical Volatility 100.04%
  • IV Percentile 97%
  • IV Rank 57.60%
  • IV High 967.13% on 04/25/24
  • IV Low 15.10% on 03/15/24
  • Put/Call Vol Ratio 111.00
  • Today's Volume 112
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 6,385
  • Open Int (30-Day) 6,781

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.75
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -0.75
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.43 +36.21%
on 06/27/24
3.60 -8.06%
on 07/15/24
+0.90 (+37.34%)
since 06/26/24
3-Month
1.91 +73.30%
on 04/29/24
3.60 -8.06%
on 07/15/24
+1.39 (+72.40%)
since 04/26/24
52-Week
1.33 +148.87%
on 11/09/23
4.30 -22.99%
on 02/21/24
+0.57 (+20.80%)
since 07/26/23

Most Recent Stories

More News
Johnson & Johnson: Taking The Bull By The Horns?

Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.

JNJ : 160.64 (+0.63%)
ABBV : 185.16 (+1.64%)
ATHA : 3.31 (-0.30%)
ASND : 133.75 (-0.47%)
AZN : 78.13 (-0.50%)
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

ATHA : 3.31 (-0.30%)
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022

Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small...

ATHA : 3.31 (-0.30%)
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022

BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

ATHA : 3.31 (-0.30%)
Why Athira Pharma Stock Imploded Today

Its mid-stage clinical trial failed to help patients with Alzheimer's.

ATHA : 3.31 (-0.30%)
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and...

ATHA : 3.31 (-0.30%)
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

ATHA : 3.31 (-0.30%)
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Athira Pharma, Inc....

ATHA : 3.31 (-0.30%)
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following...

ATHA : 3.31 (-0.30%)
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

ATHA : 3.31 (-0.30%)

Business Summary

Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 3.50
2nd Resistance Point 3.44
1st Resistance Point 3.37
Last Price 3.31
1st Support Level 3.25
2nd Support Level 3.19
3rd Support Level 3.12

See More

52-Week High 4.30
Last Price 3.31
Fibonacci 61.8% 3.16
Fibonacci 50% 2.81
Fibonacci 38.2% 2.46
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar